Sequential combined therapy with thaiidomide and narrow-band (tl01) uvb in the treatment of prurigo nodularis

C. Ferrándiz, J. M. Carrascosa, M. Just, I. Bielsa, M. Ribera

Research output: Contribution to journalArticleResearchpeer-review

49 Citations (Scopus)

Abstract

Background: Prurigo nodularis (PN) is a chronic disease of which treatment choices are limited. Among them, thaiidomide and phototherapy have been used with satisfactory results. Unfortunately, the possibility of side effects limits their use. Objective: To evaluate the efficacy of a sequential combined treatment with thaiidomide and ultraviolet B (UVB) therapy in order to minimize side effects and, thus, making possible a long-term treatment. Methods: A prospective open trial combining thaiidomide as initial therapy followed by narrow-band UVB (TL01) irradiation until complete or almost complete remission of the disease was achieved. Results: An excellent response was obtained after an average of 12 weeks of thaiidomide therapy and 32 UVB courses. Conclusions: Sequential combined therapy with thaiidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age. © 1997 S. Karger AG, Basel.
Original languageEnglish
Pages (from-to)359-361
JournalDermatology
Volume195
Issue number4
DOIs
Publication statusPublished - 1 Jan 1997

Keywords

  • Prurigo nodularis
  • Thalidomide
  • Ultraviolet B

Fingerprint Dive into the research topics of 'Sequential combined therapy with thaiidomide and narrow-band (tl01) uvb in the treatment of prurigo nodularis'. Together they form a unique fingerprint.

Cite this